Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant

Endo citizen petition asks FDA to determine that the company’s old formulation was withdrawn for safety reasons and to decline approval of ANDAs of that formulation; Purdue Pharma files third OxyContin citizen petition.